메뉴 건너뛰기




Volumn 38, Issue 2, 2008, Pages 132-140

Changes in viral loads of lamivudine-resistant mutants during entecavir therapy

Author keywords

Entecavir; Hepatitis B virus; Lamivudine; Precore; YMDD mutant

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; POLYMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTASE; UNCLASSIFIED DRUG;

EID: 38049138310     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00144.x     Document Type: Article
Times cited : (9)

References (31)
  • 1
    • 0037223033 scopus 로고    scopus 로고
    • Management of chronic hepatitis B
    • Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003; 38: S90-S103.
    • (2003) J Hepatol , vol.38
    • Conjeevaram, H.S.1    Lok, A.S.F.2
  • 2
    • 0027378724 scopus 로고
    • Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
    • Wong DK, Cheung AM, O'Rourke K, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
    • (1993) Ann Intern Med , vol.119 , pp. 312-323
    • Wong, D.K.1    Cheung, A.M.2    O'Rourke, K.3    Detsky, A.S.4    Heathcote, J.5
  • 3
    • 8544280731 scopus 로고    scopus 로고
    • Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
    • Suzuki F, Arase Y, Akuta N et al. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol 2004; 39: 969-74.
    • (2004) J Gastroenterol , vol.39 , pp. 969-974
    • Suzuki, F.1    Arase, Y.2    Akuta, N.3
  • 5
    • 0032499913 scopus 로고    scopus 로고
    • A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
    • Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
    • (1998) N Engl J Med , vol.339 , pp. 61-68
    • Lai, C.L.1    Chien, R.N.2    Leung, N.W.3
  • 6
    • 0033592764 scopus 로고    scopus 로고
    • Lamivudine as initial treatment for chronic hepatitis B in the United States
    • Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
    • (1999) N Engl J Med , vol.341 , pp. 1256-1263
    • Dienstag, J.L.1    Schiff, E.R.2    Wright, T.L.3
  • 7
    • 0033067028 scopus 로고    scopus 로고
    • Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
    • Suzuki Y, Kumada H, Ikeda K et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-8.
    • (1999) J Hepatol , vol.30 , pp. 743-748
    • Suzuki, Y.1    Kumada, H.2    Ikeda, K.3
  • 8
    • 0030875066 scopus 로고    scopus 로고
    • Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
    • Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26: 1393-5.
    • (1997) J Hepatol , vol.26 , pp. 1393-1395
    • Honkoop, P.1    Niesters, H.G.2    de Man, R.A.3    Osterhaus, A.D.4    Schalm, S.W.5
  • 9
    • 17344373482 scopus 로고    scopus 로고
    • Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term Lamivudine therapy and re-takeover by wild type after cessation of therapy
    • Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term Lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-16.
    • (1998) Hepatology , vol.27 , pp. 1711-1716
    • Chayama, K.1    Suzuki, Y.2    Kobayashi, M.3
  • 10
    • 0042743964 scopus 로고    scopus 로고
    • Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
    • Suzuki F, Tsubota A, Arase Y et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46: 182-9.
    • (2003) Intervirology , vol.46 , pp. 182-189
    • Suzuki, F.1    Tsubota, A.2    Arase, Y.3
  • 12
    • 0035114188 scopus 로고    scopus 로고
    • The polymerase L528M mutation correlates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
    • Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation correlates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-55.
    • (2001) J Clin Invest , vol.107 , pp. 449-455
    • Ono, S.K.1    Kato, N.2    Shiratori, Y.3
  • 13
    • 0034867425 scopus 로고    scopus 로고
    • Safety and efficacy of oral Entecavir given for 28days in patients with chronic hepatitis B virus infection
    • DeMan RA, Wolters LM, Nevens F et al. Safety and efficacy of oral Entecavir given for 28days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34: 578-82.
    • (2001) Hepatology , vol.34 , pp. 578-582
    • DeMan, R.A.1    Wolters, L.M.2    Nevens, F.3
  • 14
    • 0036892435 scopus 로고    scopus 로고
    • Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection
    • Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-8.
    • (2002) Gastroenterology , vol.123 , pp. 1831-1838
    • Lai, C.L.1    Rosmawati, M.2    Lao, J.3
  • 15
    • 0035890097 scopus 로고    scopus 로고
    • Long-term Entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
    • Colonno RJ, Genovesi EV, Medina I et al. Long-term Entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184: 1236-45.
    • (2001) J Infect Dis , vol.184 , pp. 1236-1245
    • Colonno, R.J.1    Genovesi, E.V.2    Medina, I.3
  • 16
    • 0000349340 scopus 로고    scopus 로고
    • Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy
    • Tassopoulos N, Hadziyannis S, Cianciara J et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34: 340A.
    • (2001) Hepatology , vol.34
    • Tassopoulos, N.1    Hadziyannis, S.2    Cianciara, J.3
  • 17
    • 26844500312 scopus 로고    scopus 로고
    • A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients
    • Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-209.
    • (2005) Gastroenterology , vol.129 , pp. 1198-1209
    • Chang, T.T.1    Gish, R.G.2    Hadziyannis, S.J.3
  • 18
    • 2442680071 scopus 로고    scopus 로고
    • Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR
    • Punia P, Cane P, Teo CG, Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004; 40: 986-92.
    • (2004) J Hepatol , vol.40 , pp. 986-992
    • Punia, P.1    Cane, P.2    Teo, C.G.3    Saunders, N.4
  • 19
    • 4344627233 scopus 로고    scopus 로고
    • Clinical emergence of Entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine
    • Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of Entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 3498-3507
    • Tenney, D.J.1    Levine, S.M.2    Rose, R.E.3
  • 20
    • 0024427902 scopus 로고
    • Mutation preventing formation of e antigen in patients with chronic HBV infection
    • Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 1989; ii: 588-91.
    • (1989) Lancet , vol.2 , pp. 588-591
    • Carman, W.F.1    Jacyna, M.R.2    Hadziyannis, S.3
  • 21
    • 0028222146 scopus 로고
    • Mutations in pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal
    • Lok ASF, Akarca US, Greene S. Mutations in pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal. Proc Natl Acad Sci USA 1994; 91: 4077-81.
    • (1994) Proc Natl Acad Sci USA , vol.91 , pp. 4077-4081
    • Lok, A.S.F.1    Akarca, U.S.2    Greene, S.3
  • 22
    • 0029817029 scopus 로고    scopus 로고
    • Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on pre-core gene expression and viral replication
    • Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on pre-core gene expression and viral replication. J Virol 1996; 70: 5845-51.
    • (1996) J Virol , vol.70 , pp. 5845-5851
    • Buckwold, V.E.1    Xu, Z.2    Chen, M.3    Yen, T.S.4    Ou, J.H.5
  • 23
    • 0033760350 scopus 로고    scopus 로고
    • Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy
    • Cho SW, Hahm K-B, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1163-9.
    • (2000) Hepatology , vol.32 , pp. 1163-1169
    • Cho, S.W.1    Hahm, K.-B.2    Kim, J.H.3
  • 24
    • 0036893202 scopus 로고    scopus 로고
    • Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy
    • Suzuki F, Suzuki Y, Tsubota A et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002; 37: 824-30.
    • (2002) J Hepatol , vol.37 , pp. 824-830
    • Suzuki, F.1    Suzuki, Y.2    Tsubota, A.3
  • 25
    • 33745726960 scopus 로고    scopus 로고
    • Changes in viral load of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy
    • Suzuki F, Kumada H, Nakamura H. Changes in viral load of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 2006; 78: 1025-34.
    • (2006) J Med Virol , vol.78 , pp. 1025-1034
    • Suzuki, F.1    Kumada, H.2    Nakamura, H.3
  • 26
    • 0024605518 scopus 로고
    • Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
    • Newton CR, Graham A, Heptinstall LE et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17: 2503-16.
    • (1989) Nucleic Acids Res , vol.17 , pp. 2503-2516
    • Newton, C.R.1    Graham, A.2    Heptinstall, L.E.3
  • 27
    • 0029082116 scopus 로고
    • A novel method for efficient amplification of whole hepatitis B virus genomes permit rapid functional analysis and reveals deletion mutants in immunosuppressed patients
    • Günther S, Li BC, Miska S, Krüger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permit rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69: 5437-44.
    • (1995) J Virol , vol.69 , pp. 5437-5444
    • Günther, S.1    Li, B.C.2    Miska, S.3    Krüger, D.H.4    Meisel, H.5    Will, H.6
  • 28
    • 0037235229 scopus 로고    scopus 로고
    • Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD motif mutant and risk of breakthrough hepatitis - An open-cohort study
    • Akuta N, Tsubota A, Suzuki F et al. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD motif mutant and risk of breakthrough hepatitis - an open-cohort study. J Hepatol 2003; 38: 91-7.
    • (2003) J Hepatol , vol.38 , pp. 91-97
    • Akuta, N.1    Tsubota, A.2    Suzuki, F.3
  • 29
    • 0036858638 scopus 로고    scopus 로고
    • Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
    • Suzuki F, Tsubota A, Akuta N et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 2002; 37: 922-7.
    • (2002) J Gastroenterol , vol.37 , pp. 922-927
    • Suzuki, F.1    Tsubota, A.2    Akuta, N.3
  • 30
    • 0035991863 scopus 로고    scopus 로고
    • Efficacies of Entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro
    • Levine S, Hernandez D, Yamanaka G etal. Efficacies of Entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 2525-32.
    • (2002) Antimicrob Agents Chemother , vol.46 , pp. 2525-2532
    • Levine, S.1    Hernandez, D.2    Yamanaka, G.3
  • 31
    • 1242337438 scopus 로고    scopus 로고
    • Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy
    • Werle B, Cinquin K, Marcellin P et al. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat 2004; 11: 74-83.
    • (2004) J Viral Hepat , vol.11 , pp. 74-83
    • Werle, B.1    Cinquin, K.2    Marcellin, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.